Cancer chemopreventive effects of polyunsaturated fatty acids. 2004

Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
College of Science and Technology, Nihon University, 1-8 Kanda Surugadai, Chiyoda-ku, Tokyo 101-8308, Japan. akihisa@chem.cst.nihon-u.ac.jp

The inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), in Raji cells as a primary screening test for anti-tumor promoters, for 22 fatty acids (as free and esterified forms), including 10 di- and polyunsaturated acids, and the inhibitory effects on activation of (+/-)-(E)-methtyl-2-[(E)-hydroxy-imino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor, as a primary screening test for anti-tumor initiators, for 17 fatty acids (as methyl ester forms), were evaluated. Among the fatty acids tested, three n-3 polyunsaturated acids, eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), exhibited potent inhibitory effects both on EBV-EA and NOR 1 activation. Furthermore, DHA methyl ester exhibited remarkable anti-tumor-promoting activity on an in vivo two-stage carcinogenesis test of mouse tumor using 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and TPA as a promoter.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D005231 Fatty Acids, Unsaturated FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. Fatty Acids, Polyunsaturated,Polyunsaturated Fatty Acid,Unsaturated Fatty Acid,Polyunsaturated Fatty Acids,Acid, Polyunsaturated Fatty,Acid, Unsaturated Fatty,Acids, Polyunsaturated Fatty,Acids, Unsaturated Fatty,Fatty Acid, Polyunsaturated,Fatty Acid, Unsaturated,Unsaturated Fatty Acids
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D013755 Tetradecanoylphorbol Acetate A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA. Phorbol Myristate Acetate,12-Myristoyl-13-acetylphorbol,12-O-Tetradecanoyl Phorbol 13-Acetate,Tetradecanoylphorbol Acetate, 4a alpha-Isomer,12 Myristoyl 13 acetylphorbol,12 O Tetradecanoyl Phorbol 13 Acetate,13-Acetate, 12-O-Tetradecanoyl Phorbol,Acetate, Phorbol Myristate,Acetate, Tetradecanoylphorbol,Myristate Acetate, Phorbol,Phorbol 13-Acetate, 12-O-Tetradecanoyl,Tetradecanoylphorbol Acetate, 4a alpha Isomer
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D020030 Nitric Oxide Donors A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81) Nitric Oxide Donor,Donor, Nitric Oxide,Donors, Nitric Oxide,Oxide Donor, Nitric,Oxide Donors, Nitric

Related Publications

Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
September 2013, Journal of cancer prevention,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
February 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
September 2000, La Revue du praticien,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
December 1984, Recenti progressi in medicina,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
July 1986, The Journal of infectious diseases,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
July 2017, Clinical nutrition research,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
January 1974, Nutrition and metabolism,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
January 1999, Lipids,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
November 1973, British medical journal,
Toshihiro Akihisa, and Harukuni Tokuda, and Masakazu Ogata, and Motohiko Ukiya, and Masao Iizuka, and Takashi Suzuki, and Koichi Metori, and Naoto Shimizu, and Hoyoku Nishino
January 1973, The Mount Sinai journal of medicine, New York,
Copied contents to your clipboard!